Diagnostic and Prognostic Potential of Circulating Long Non-Coding RNAs in Non Small Cell Lung Cancer

Peng, Wei; Wang, Jun; Shan, Bin; Zhang, Peng; Dong, Yeping; Shi, Weisong; He, Dan; Cheng, Yuanda; Zhao, Wenyuan; Zhang, Chunfang; Li, Bin; Duan, Chaojun

doi:10.1159/000493043

Cited by 45 publications

(35 citation statements)

References 82 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Functional assays further showed that PART1 knockdown‐mediated anti‐proliferation, anti‐migration, and anti‐invasion effects were suppressed via JAK1 or JAK3 overexpression in NSCLC, in line with that of Wang et al Further xenograft tumor growth model of NSCLC also confirmed the antitumor genesis role of PART1 knocking down via inactivation of JAK‐STAT signaling pathway. Although a large number of lncRNAs are considered as diagnostic and prognostic markers as well as therapeutic targets for NSCLC, due to complicated pathogenesis of NSCLC, more molecular mechanisms involved in NSCLC need to be further explored. Moreover, the further study of PART1 on regulation of AS is still indispensable to be investigated via more elaborate animal models.…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA PART1 promotes progression of non‐small cell lung cancer cells via JAK‐STAT signaling pathway

Zhu

Wang

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Non‐small cell lung cancer (NSCLC), the major type of lung cancer, becomes the greatest threat to the life of people. Growing evidence shows prostate androgen‐regulated transcript 1 (PART1) is considered as effective markers for prostate cancer, and has been shown to be associated with poor prognosis of NSCLC. However, the tumorigenic mechanism of PART1 in NSCLC remains to be investigated. In this study, we found that the expression of PART1 was robustly induced in NSCLC tissues and cell lines. Functional studies established that overexpression of PART1 could promote NSCLC cell proliferation, migration, and invasion, while interference of PART1 inhibited NSCLC progression. Our results also identified miR‐635 as a novel target of PART1, whose expression was inhibited by PART1 in NSCLC cell lines. Moreover, gain‐ and loss‐of‐function studies revealed that PART1 could sponge miR‐635 and increase the expression of Janus kinase (JAK) and signal transducer and activator of transcription proteins (STATs). Finally, we deciphered the molecular mechanism by which PART1 contributed to promotion of NSCLC cell progression via phosphorylation and activation of JAK‐STAT signaling pathway. The animal experiment further confirmed that interference of NSCLC could suppress in vivo tumorigenic ability of NSCLC with favorable pharmacological activity via inactivation of JAK‐STAT signaling pathway. In conclusion, our findings clarified the biologic significance of PART1/miR‐635/JAK‐STAT axis in NSCLC progression and provided novel evidence that PART1 may be a new potential therapeutic target for the treatment of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA PART1 promotes progression of non‐small cell lung cancer cells via JAK‐STAT signaling pathway

Zhu

Wang

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Lung cancer is one of the cancers with high morbidity and mortality, which consists of more than 50 histological subtypes (1,2). Non-small cell lung cancer (NSCLC) is the dominant type, accounting for about 80% of lung cancers (3). The combination of conventional platinum chemotherapy and radiotherapy is the standard therapy for locally advanced unresectable NSCLC (4).…”

Section: Introductionmentioning

confidence: 99%

Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway

et al. 2020

View full text Add to dashboard Cite

Background: The application of apatinib is immensely limited by its acquired drug resistance. This research investigates whether cordycepin, a component from Cordyceps could synergize with apatinib to improve its anticancer effect on non-small cell lung cancer (NSCLC) cells. Methods: The NSCLC cell lines A549, PC9, and H1993, and human bronchial epithelial (HBE) cell line Bears-2B were used in this study. Cell counting kit 8, colony formation assays, wound healing assay, transwell assay, and flow cytometry analysis were performed to assess the cell viability, the migration ability, and invasion ability of the cells. Kyoto encyclopedia of genes and genomes (KEGG), western blotting and molecular docking was applied to analyze the possible pathways affected by cordycepin. Results: The combination of cordycepin and apatinib in a ratio of 5:1 synergistically reduced proliferation of NSCLC cells, inhibited cell migration and invasion, increased cell apoptosis by altering cell cycle in NSCLC A549 and PC9 cells. The VEGF/PI3K/Akt pathway was inhibited after treatment with cordycepin and apatinib. Conclusion: Our findings demonstrated that the combination of cordycepin and apatinib has synergistically anticancer effect on NSCLC cells by down-regulating VEGF/PI3K/Akt signaling pathway. This result indicated that cordycepin and apatinib could be a promising drug combination against NSCLC.

show abstract

“…Five NSCLC datasets (GSE19804, GSE27262, GSE43458, GSE75037, GSE103512), including 308 tumor samples and 207 normal lung samples, were downloaded from GEO (https://www.ncbi.nlm.nih.gov/geo). The inclusion criteria for these datasets were as follows: (1) primary NSCLC histology; (2) no history of radiotherapy or chemotherapy; and (3) more than 50 pathological specimens on each chip. The GSE19804, GSE23066, and GSE27262 datasets were generated from the same detecting microarray platform ([HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array), whereas the GSE43458, GSE75037, and GSE103512 data sets were…”

Section: Nsclc Transcriptome Microarray Datasetmentioning

confidence: 99%

PLEK2 and SCN7A: novel biomarkers of non-small cell lung cancer

Liu

Chang

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective Lung cancer is the leading cause of cancer-related death globally, and non-small cell lung cancer (NSCLC) is the most common type of lung cancer. However, the diagnosis and prognosis of NSCLC remain dim. Our team has focused on identifying differentially expressed genes (DEGs) between NSCLC tissues and adjacent tissues, which may be useful as effective diagnostic markers that can better explain the progression of NSCLC. Methods The Gene Expression Omnibus (GEO) database was used to screen the Gene Expression Omnibus series, which records the information of a large number of patients with primary NSCLC (n > 50). Then, the DEGs were validated using Student’s t -test. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using DAVID. The prognosis information was analyzed separately using data obtained from three databases, Human Protein Atlas, Kaplan–Meier Plotter, and SurvExpress. Results A series of 180 DEGs (33 upregulated and 147 downregulated genes), mainly involving genes associated with extracellular exosomes, focal adhesion, and cell adhesion, were identified via GO analysis. Subsequently, KEGG analysis demonstrated that focal adhesion, cell adhesion molecules, and PPAR signaling pathway were the most enriched pathways. Then, we paid particular attention to pleckstrin 2 (PLEK2) and sodium voltage-gated channel alpha subunit 7 (SCN7A), as they have not been investigated as cancer-related genes previously. Kaplan–Meier survival analysis illustrated that PLEK2 and SCN7A levels were significantly correlated with the prognosis of NSCLC. Conclusions Our research found that, as potential biomarkers, both PLEK2 and SCN7A are related to the development and prognosis of NSCLC. They may be used in disease screening and prognosis. The clinical significance of these two genes deserves further investigation.

show abstract

Diagnostic and Prognostic Potential of Circulating Long Non-Coding RNAs in Non Small Cell Lung Cancer

Cited by 45 publications

References 82 publications

Long noncoding RNA PART1 promotes progression of non‐small cell lung cancer cells via JAK‐STAT signaling pathway

Long noncoding RNA PART1 promotes progression of non‐small cell lung cancer cells via JAK‐STAT signaling pathway

Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway

PLEK2 and SCN7A: novel biomarkers of non-small cell lung cancer

Contact Info

Product

Resources

About